A. Keith Stewart

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja et al. · Journal of Clinical Oncology · 2022 · 633 citations · Full text

Medicine, Hematology, Immunology +17

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Suzanne Trudel, Zhihua Li, Ellen Wei et al. · Blood · 2004 · 289 citations · Full text

Medicine, Oncology, Pharmacology +14

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

Suzanne Trudel, Zhihua Li, Jennifer Rauw et al. · Blood · 2007 · 217 citations · Full text

Medicine, Oncology, Pharmacology +11